Edition:
India

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

19.78USD
12:32am IST
Change (% chg)

$-0.04 (-0.20%)
Prev Close
$19.82
Open
$19.90
Day's High
$20.09
Day's Low
$19.67
Volume
394,438
Avg. Vol
829,427
52-wk High
$25.31
52-wk Low
$15.06

Latest Key Developments (Source: Significant Developments)

Exelixis Further Expands Prostate Cancer Cohort In Phase 1B Cosmic-021 Trial Of Cabozantinib
Tuesday, 7 Jan 2020 

Jan 7 (Reuters) - Exelixis Inc ::EXELIXIS FURTHER EXPANDS PROSTATE CANCER COHORT IN PHASE 1B COSMIC-021 TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS.EXELIXIS INC - METASTATIC CASTRATION-RESISTANT PROSTATE CANCER COHORT FURTHER EXPANDED TO 130 PATIENTS.EXELIXIS - 50 MORE PATIENTS WITH METASTATIC CRPC WITH HISTOLOGICALLY/CYTOLOGICALLY CONFIRMED ADENOCARCINOMA OF PROSTATE ARE BEING ENROLLED IN TRIAL.  Full Article

Exelixis To Collaborate With Roche for Three Phase 3 Combination Trials In Patients with Advanced Solid Tumors
Thursday, 19 Dec 2019 

Dec 19 (Reuters) - Exelixis Inc ::EXELIXIS INC - CLINICAL PROGRAM EXPECTED TO INCLUDE ONE PHASE 3 PIVOTAL TRIAL IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC).EXELIXIS INC - CLINICAL PROGRAM EXPECTED TO ALSO INCLUDE ONE PHASE 3 PIVOTAL TRIAL IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC).EXELIXIS INC - CLINICAL PROGRAM EXPECTED TO ALSO INCLUDE ONE PHASE 3 PIVOTAL TRIAL IN RENAL CELL CARCINOMA (RCC).EXELIXIS ENTERS INTO A CLINICAL COLLABORATION FOR THREE PHASE 3 COMBINATION TRIALS FOR PATIENTS WITH ADVANCED SOLID TUMORS.EXELIXIS INC - ANNOUNCED COLLABORATION AGREEMENT WITH ROCHE TO EVALUATE CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB.EXELIXIS INC - CLINICAL PROGRAM WILL BE CO-FUNDED BY COMPANIES.  Full Article

Exelixis Enters Into A Clinical Collaboration For Three Phase 3 Combination Trials For Patients With Advanced Solid Tumors
Thursday, 19 Dec 2019 

Dec 19 (Reuters) - Exelixis Inc ::EXELIXIS ENTERS INTO A CLINICAL COLLABORATION FOR THREE PHASE 3 COMBINATION TRIALS FOR PATIENTS WITH ADVANCED SOLID TUMORS.EXELIXIS INC - ANNOUNCED COLLABORATION AGREEMENT WITH ROCHE TO EVALUATE CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB.EXELIXIS INC - CLINICAL PROGRAM WILL BE CO-FUNDED BY COMPANIES.EXELIXIS INC - CLINICAL PROGRAM EXPECTED TO INCLUDE THREE PHASE 3 PIVOTAL TRIALS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC).EXELIXIS INC - CLINICAL PROGRAM EXPECTED TO ALSO INCLUDE THREE PHASE 3 PIVOTAL TRIALS IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC).EXELIXIS INC - CLINICAL PROGRAM EXPECTED TO ALSO INCLUDE THREE PHASE 3 PIVOTAL TRIALS IN RENAL CELL CARCINOMA (RCC).  Full Article

Exelixis’ Partner Ipsen Announces Health Canada’S Approval Of Cabometyx Tablets
Tuesday, 12 Nov 2019 

Nov 12 (Reuters) - Exelixis Inc ::EXELIXIS’ PARTNER IPSEN ANNOUNCES HEALTH CANADA’S APPROVAL OF CABOMETYX® (CABOZANTINIB) TABLETS FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA.EXELIXIS INC - PARTNER IPSEN BIOPHARMACEUTICALS CANADA INC. RECEIVED HEALTH CANADA APPROVAL OF CABOMETYX TABLETS.EXELIXIS INC - WILL RECEIVE A MILESTONE PAYMENT OF $2 MILLION FOR HEALTH CANADA APPROVAL.EXELIXIS INC - HEALTH CANADA APPROVAL WAS BASED ON RESULTS FROM CELESTIAL PHASE 3 PIVOTAL TRIAL OF CABOMETYX FOR PATIENTS WITH ADVANCED HCC.EXELIXIS INC - CABOMETYX DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OVERALL SURVIVAL VERSUS PLACEBO.  Full Article

Exelixis Says Daiichi Sankyo Announced Positive Results From Phase 3 Pivotal Trial Of Esaxerenone
Friday, 8 Nov 2019 

Nov 7 (Reuters) - Exelixis Inc ::EXELIXIS’ COLLABORATOR DAIICHI SANKYO ANNOUNCES POSITIVE RESULTS FROM PHASE 3 PIVOTAL TRIAL OF ESAXERENONE IN PATIENTS WITH DIABETIC NEPHROPATHY.ESAXERENONE HAS BEEN APPROVED AS A TREATMENT FOR PATIENTS WITH HYPERTENSION IN JAPAN, WHERE IT IS MARKETED AS MINNEBRO TABLETS.DAIICHI SANKYO IS SOLELY RESPONSIBLE FOR ESAXERENONE'S DEVELOPMENT AND COMMERCIALIZATION.PRIMARY ENDPOINT OF STUDY IS RATE OF REMISSION OF MICROALBUMINURIA AFTER 52-WEEK TREATMENT.EXELIXIS -FOR ESAXERENONE, CO ELIGIBLE FOR SUBSTANTIAL COMMERCIALIZATION MILESTONES, LOW DOUBLE-DIGIT ROYALTIES ON SALES, AS IT ADVANCES.STUDY SHOWED THAT ESAXERENONE-BASED REGIMEN RESULTED IN A SIGNIFICANTLY HIGHER UACR REMISSION RATE AS COMPARED TO PLACEBO.  Full Article

Exelixis Announces Third Quarter 2019 Financial Results And Provides Corporate Update
Thursday, 31 Oct 2019 

Oct 30 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 NON-GAAP EARNINGS PER SHARE $0.34.Q3 GAAP EARNINGS PER SHARE $0.31.Q3 REVENUE $271.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $228.1 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $0.19 -- REFINITIV IBES DATA.  Full Article

Exelixis - FDA Website Indicates That An ANDA Was Submitted To FDA For Cabometyx(Reg) Tablets
Friday, 27 Sep 2019 

Sept 26 (Reuters) - Exelixis Inc ::EXELIXIS - FDA WEBSITE INDICATES THAT AN ANDA WAS SUBMITTED TO FDA ON AUG. 16, FOR GENERIC VERSION OF CO'S CABOMETYX(REG) TABLETS (20 MG/40 MG/60 MG).EXELIXIS INC - CO HAS NOT RECEIVED NOTICE OF A PARAGRAPH IV CERTIFICATION WITH RESPECT TO ANDA FILING FOR CO'S CABOMETYX(REG) TABLETS.EXELIXIS INC - EXELIXIS INTENDS TO ENFORCE ITS INTELLECTUAL PROPERTY RIGHTS RELATING TO CABOMETYX.  Full Article

Exelixis Posts Q2 Earnings Per Share Of $0.25
Thursday, 1 Aug 2019 

July 31 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 NON-GAAP EARNINGS PER SHARE $0.29.Q2 GAAP EARNINGS PER SHARE $0.25.Q2 REVENUE $240.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $227.8 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.24 -- REFINITIV IBES DATA.UPDATES FINANCIAL GUIDANCE FOR FULL YEAR 2019.SEES 2019 COST OF GOODS SOLD IS EXPECTED TO BE BETWEEN 4% AND 5% OF NET PRODUCT REVENUES.SEES 2019 RESEARCH AND DEVELOPMENT EXPENSES TO BE BETWEEN $330 MILLION AND $350 MILLION.SEES 2019 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES TO BE BETWEEN $220 MILLION AND $240 MILLION.  Full Article

Exelixis And Aurigene Enter Into Exclusive Collaboration
Thursday, 1 Aug 2019 

July 31 (Reuters) - Exelixis Inc ::EXELIXIS AND AURIGENE ENTER INTO EXCLUSIVE COLLABORATION, OPTION AND LICENSE AGREEMENT TO DISCOVER AND DEVELOP NOVEL THERAPIES FOR CANCER.EXELIXIS INC - COMPANIES WILL PARTNER TO ADVANCE SMALL MOLECULES IN UP TO SIX DISCRETE PROJECTS.EXELIXIS INC - WILL MAKE AN UPFRONT PAYMENT OF $10 MILLION FOR EXCLUSIVE OPTIONS TO LICENSE THREE PREEXISTING PROGRAMS FROM AURIGENE.EXELIXIS INC - WILL ALSO CONTRIBUTE RESEARCH FUNDING TO AURIGENE TO FACILITATE DISCOVERY AND PRECLINICAL DEVELOPMENT WORK ON ALL SIX PROGRAMS.EXELIXIS INC - AURIGENE RETAINS LIMITED DEVELOPMENT AND COMMERCIAL RIGHTS FOR INDIA AND RUSSIA.  Full Article

Exelixis Updates Phase 1b Cosmic-021 Trial Of Cabozantinib In Combination With Atezolizumab In Patients With Advanced Solid Tumors
Monday, 15 Jul 2019 

July 15 (Reuters) - Exelixis Inc ::EXELIXIS UPDATES PHASE 1B COSMIC-021 TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS.EXELIXIS INC - FOUR COHORTS ADDED FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER BASED ON ENCOURAGING EARLY DATA.EXELIXIS INC - ORIGINAL METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND IMMUNOTHERAPY-REFRACTORY NON-SMALL CELL LUNG CANCER COHORTS EXPANDED TO 80 SUBJECTS.  Full Article